Poolbeg claims POLB 001 could be at $10 billion market opportunity

12 February 2024
poolbeg_large

UK-based Poolbeg Pharma (AIM: POLB) has announced that research conducted on its behalf confirms a market opportunity of at least $10 billon for POLB 001 in cancer immunotherapy-induced cytokine release syndrome (CRS) as an orally-delivered preventative therapy.

Cancer immunotherapies have been approved in rare and orphan blood cancers and so Poolbeg can see potential for POLB 001 in one or more of these cancer types.

"There is also a very active M&A market in this sector"POLB 001 in cancer immunotherapy-induced CRS will be developed alongside the company's existing portfolio of assets including its influenza program, its AI drug discovery work and oral delivery of GLP-1 for obesity and other metabolic diseases.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical